Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity	
BAR	D1 LIFE SCIENCES LIMITED	
ABN 58 00	09 070 384	
We (the entity) give ASX the following	g information.
-	t 1 - All issues nust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	CEO Options
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	10,000,000
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Options are exercisable at \$0.035 each on or before 4 October 2023

Do the *securities rank equally 4 in all respects from the +issue date with an existing +class of Options do not have the right to participate in quoted +securities? new issues of Shares or other securities in the Company, including by way of bonus issues, If the additional +securities do rights issues or otherwise, unless the Options not rank equally, please state: have been exercised into Shares before the the date from which they do record date for determination of entitlements to the extent to which they a new issue. participate for the next dividend, (in the case of a distribution) trust, interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration NIL Issued in consideration for services provided by Purpose of the issue 6 the CEO in her role of Chief Executive Officer of (If issued as consideration for the acquisition of assets, clearly the Company and as an incentive for future performance identify those assets) Is the entity an +eligible entity Yes 6a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder Annual General Meeting 30 November 2018 6b resolution under rule 7.1A was passed 10,000,000 CEO Options Number of *securities issued 6c without security holder approval

Nil

under rule 7.1

under rule 7.1A

Number of +securities issued

with security holder approval

6d

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	NIL
6f	Number of *securities issued	NIL
01	under an exception in rule 7.2	INIL
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Appendix 1
7	+Issue dates	4 October 2019
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	
	Cross reference: item 33 of Appendix 3B.	

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
1,367,185,026	Fully Paid Ordinary Shares

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
217,003,236	Performance Shares (subject to milestones) expiring on 9 June 2021.
2,000,000	Adviser Options, each exercisable at \$0.0128 on or before 20 February 2022
10,000,000	CEO Options, each exercisable at \$0.035 expiring 4 October 2019

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Nil			

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A

⁺ See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A

28	Date rights trading will begin (if applicable)	N/A	
29	Date rights trading will end (if applicable)	N/A	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A	
33	⁺ Issue date	N/A	
	3 - Quotation of securitie If any complete this section if you are ap Type of *securities		
(a)	(tick one) +Securities described in Part 1		
(b)	All other ⁺ securities		
	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es that have ticked box 34(a)		
Addit	ional securities forming a new	v class of securities	
Tick to docume	indicate you are providing the informatents	tion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	held by those holders If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000		

⁺ See chapter 19 for defined terms.

	100,001 and over
37	A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		ı	
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: 9 Celler Date: 4 October 2019

Company Secretary
Print name: Pauline Collinson

== == == ==

04/03/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	828,662,397		
Add the following:	47 December 2040		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	17 December 2018 165,732,775 ordinary shares 12 July 2019 124,289,854 ordinary shares		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval			
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period			
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil		
"A"	1,118,685,026		

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
Multiply "A" by 0.15	167,802,753		
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.1		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period not counting those issued:	149,060,483 Ordinary Shares issued pursuant to the Placement on 18 June 2019 10,000,000 CEO Options		
• Under an exception in rule 7.2	10,000,000 GEO Options		
• Under rule 7.1A			
 With security holder approval under rule 7.1 or rule 7.4 			
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 			
"C"	159,060,483		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining		
"A" x 0.15	167,802,753		
Note: number must be same as shown in Step 2			
Subtract "C"	159,060,483		
Note: number must be same as shown in Step 3			
Total ["A" x 0.15] – "C"	8,742,270		

04/03/2013 Appendix 3B Page 11

[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
		"A"
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	111,868,502	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	99,439,517 Ordinary Shares issued pursuant to the Placement on 18 June 2019	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	99,439,517	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	111,868,502
Note: number must be same as shown in Step 2	
Subtract "E"	99,439,517
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	12,428,985
	Note: this is the remaining placement capacity under rule 7.1A

04/03/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.